ERBB2 and triple-negative breast carcinoma: The patients were divided into the pCR-positive and pCR-negative groups-the latter comprising patients with partial response (<i>n</i> = 61) and stable disease (<i>n</i> = 90)-and were classified into four molecular subtypes: Luminal A/B, HER2-enriched, and triple-negative breast cancer (TNBC).